Source link : https://www.newshealth.biz/health-news/novel-regimens-yield-high-response-rates-for-older-hodgkin-lymphoma-patients/
Older patients with classical Hodgkin lymphoma unsuitable for conventional chemotherapy had high rates of durable responses with two brentuximab vedotin (BV; Adcetris) regimens, one that omitted chemotherapy, a small prospective study showed. Brentuximab plus the alkylating agent dacarbazine (DTIC) produced an objective response rate (ORR) of 95% in 22 patients, whereas brentuximab plus nivolumab (Opdivo) […]
Author : News Health
Publish date : 2024-03-06 17:27:15
Copyright for syndicated content belongs to the linked Source.
Categories